Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Priority Reviews May Have Helped Reduce New Drug Shortages

Executive Summary

But agency's policy changes have failed to ameliorate ongoing shortages, GAO finds.

You may also be interested in...

US FDA's Drug Shortage Effort Questioned By GAO

GAO's 'high risk' report lowers FDA grade for its drug shortage action plans, saying efforts have not been sustained.

Drug Pricing Panacea Or Just PR Victory? Expedited ANDAs May Have Limited Impact

In theory, reviewing generic applications faster should speed competition; in practice, FDA's new policy likely won't make too much difference.

FDA Drug Shortage Advice: Talk To Us Early; We’ll Be Discreet

Manufacturers shouldn’t be afraid to work with FDA on preventing drug shortages for fear of public shaming, agency says.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts